New study aims to reduce unnecessary pancreatic surgery with smarter biomarkers

NCT ID NCT06694792

Recruiting now Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking for new biomarkers to tell which pancreatic cysts (IPMNs) are likely to become cancerous. Researchers will analyze genetic, metabolic, and lifestyle data from 800 patients to develop a risk score. The goal is to help doctors decide who truly needs surgery and who can safely avoid it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could give doctors a new tool to predict which pancreatic cysts are dangerous, helping avoid unnecessary surgery.
What could go wrong: This is an observational study, not a treatment trial. It is still early, and the biomarkers found may not prove accurate enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IPMN, PANCREATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreas disorder Pancreatic Intraductal Neoplasms pancreatic intraductal papillary-mucinous neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IPMN, PANCREATIC

Contacts and locations

Locations

San Raffaele Hospital
RECRUITING

Milan, MI, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.